OBJECTIVE: T helper 17 (Th17) cells play important roles in adaptive immunity and are involved in several inflammatory and autoimmune diseases, but little is known about their role in tumour immunity. The current study investigated the involvement of Th17 cells in multiple myeloma. METHODS: Flow cytometry was used to investigate the frequencies of Th17 cells in peripheral blood mononuclear cells from 30 patients with multiple myeloma and from 14 healthy control subjects. The concentrations of Th17-associated cytokines (interleukin [IL]-6, IL-17, IL-1b and IL-23) were measured by enzyme-linked immunosorbent assay. RESULTS: There was a significantly increased proportion of Th17 cells, and increased plasma concentrations of Th17-associated cytokines, in patients with multiple myeloma compared with healthy controls. There was a significant relationship between the proportion of Th17 cells and clinical tumour stage, serum lactate dehydrogenase concentration and serum creatinine concentration. CONCLUSIONS: Th17 cells might be important therapeutic targets in multiple myeloma and could facilitate a better outcome for tumour immunotherapy.
Introduction
Multiple myeloma is a plasma cell malignancy, characterized by the clonal expansion of plasma cells and the systemic damage caused by circulating monoclonal protein. 1 Multiple myeloma is one of the most frequently occurring haematological malignancies and remains incurable, despite advances in systemic and supportive therapies. 2, 3 Although there is accumulating evidence of the crucial role played by the immune system in malignant tumours, the precise mechanisms by which the immune system is modulated in patients with multiple myeloma remain elusive.
A novel CD4 + T helper 17 cell type, Th17, has been identified in mice and in humans. 4, 5 Th17 cells are defined as CD4 + T helper cells that secrete the cytokine interleukin (IL)-17. Their developmental programme is controlled by multiple cytokines and the transcription factor retinoic acid receptorrelated orphan receptor-γt. 6 Th17 cells have risen to prominence in studies of C-J Shen, Z-H Yuan, Y-X Liu et al. Th17 cells in multiple myeloma inflammation and autoimmune disease. 7, 8 While their role in the pathogenesis of many of these conditions is well defined, their function in the context of tumour immunology remains controversial. 6, 9 The present study investigated the frequency of Th17 cells, the plasma concentrations of Th17 associated cytokines (IL-1β, IL-6, IL-17 and IL- 23) , and the relationship between the prevalence of Th17 cells and various clinicopathological characteristics in patients with multiple myeloma.
Patients and methods

STUDY POPULATION
Patients with newly diagnosed and untreated multiple myeloma were sequentially enrolled in this case-control study between January 2009 and June 2011 by the Department of Haematology, the First Hospital of Zhuzhou City, Zhuzhou City, China. The diagnosis of multiple myeloma was based on the International Myeloma Working Group criteria 10 and patients were classified according to the international staging system for multiple myeloma. 11 Age-matched healthy individuals attending the First Hospital of Zhuzhou City, Zhuzhou City, China for routine examination were recruited as control subjects. Patients and control subjects with any inflammatory or autoimmune diseases were excluded from the study.
Patients were treated with conventional chemotherapy regimens (i.e. vincristine/ adriamycin (doxorubicin)/dexamethasone [VAD], thalidomide/prednisone or bortezomib/dexamethasone). VAD treatment comprised four 4-week cycles of 0.4 mg/day vincristine and 9 mg/m 2 per day doxorubicin, administered via continuous intravenous (i.v.) infusion on days 1 -4, plus 40 mg/day dexamethasone given orally on days 1 -4, 9 -12 and 17 -20. Thalidomide/ prednisone treatment comprised three 4-week cycles of 40 mg/m 2 per day prednisone, administered orally on days 1 -4, 9 -12 and 17 -20, with 200 mg/day thalidomide given orally. Bortezomib plus dexamethasone treatment comprised four 3week cycles of 1.3 mg/m 2 per day bortezomib, administered via bolus i.v. injection on days 1, 4, 8 and 11, plus 40 mg/day dexamethasone given orally on days 1 -4 (all cycles) and days 9 -12 (cycles 1 and 2). Treatment response was assessed according to the International Myeloma Working Group criteria. 12 This study was approved by the Ethical Committee of the First Hospital of Zhuzhou City. Written informed consent was obtained from all study participants.
SERUM LDH AND CREATININE MEASUREMENT
Blood samples were obtained from all study participants and used immediately. Serum was collected by allowing samples to stand and clot for 30 min at room temperature, followed by centrifugation at 200 g for 5 min. Serum lactate dehydrogenase (LDH) concentrations were measured using an automated chemistry analyser (RA-50 Chemistry System; Siemens, Erlangen, Germany) and serum creatinine was measured with a commercially available kit (ab65340; Abcam ® , Cambridge, MA, USA).
PBMC ISOLATION AND PLASMA COLLECTION
Uncoagulated peripheral whole blood samples (containing 15 IU/ml heparin) were obtained from all study participants. Peripheral blood mononuclear cells (PBMCs) were isolated from these samples by Ficoll-Paque™ (1.077 g/ml; GE Healthcare Biosciences, Piscataway, NJ, USA) density C-J Shen, Z-H Yuan, Y-X Liu et al. Th17 cells in multiple myeloma gradient centrifugation at 800 g for 20 min. PBMCs were cultured in RPMI 1640 medium supplemented with 100 U/ml penicillin, 100 U/ml streptomycin, 2 mM glutamine, 25 mmol/l 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid, 50 µmol/l βmercaptoethanol and 10% heat-inactivated fetal calf serum (Invitrogen, Carlsbad, CA, USA) at 1 × 10 6 cells/ml for 4 h.
Plasma was obtained by centrifugation of uncoagulated peripheral blood samples (containing 15 IU/ml heparin) at 300 g for 5 min, which was then stored at -80°C until cytokine levels were measured.
LABELLING AND FLOW CYTOMETRY ANALYSIS OF TH17 CELLS
The PBMCs were stimulated for 4 h with 50 ng/ml phorbol 12-myristate 13-acetate and 1 µg/ml ionomycin in the presence of 10 µg/ml brefeldin A (Sigma-Aldrich, St Louis, MO, USA) at 37°C, before intracellular labelling. After stimulation, 2 × 10 6 cells were labelled with specific fluorescein-conjugated antihuman antibodies against CD3 and CD4, together with one of CD25, CD95, CD95L, CD45RO, CD45RA, chemokine C-X-C motif receptor 4 (CXCR4), chemokine C-C motif receptor (CCR)5, CCR6, CCR7, L-selectin (CD62L), human leucocyte antigen (HLA)-DR, programmed cell death-1 (PD-1), B7 homologue 1 (B7-H1; CD274), or B7-H4, at 4°C for 30 min (all antibodies were from eBioscience, San Diego, CA, USA). Cells were washed twice with phosphate buffered saline (PBS; 290 mOsm/kg, pH 7.30).
After surface labelling, cells were fixed and permeabilized using the BD Cytofix/ Cytoperm™ fixation/permeabilization solution kit with BD GolgiPlug™ (Becton, Dickinson and Co., Franklin Lakes, NJ, USA), according to the manufacturer's instructions. CD3/CD4-labelled cells were then labelled with fluorescein-conjugated antibodies against human IL-17A, together with one of IL-2, IL-4, IL-10, interferon (IFN)-γ, transforming growth factor (TGF)-β, forkhead box P3 (FoxP3) or granzyme B (all antibodies from eBioscience) at 4°C for 30 min, and washed twice with PBS.
Cells were labelled with a maximum of four antibodies (against CD3, CD4 and IL-17A, plus one other) for four-colour flowcytometric analysis. Isotype control antibodies were used to determine the background fluorescence. Flow cytometry was performed using an EPICS™ Elite ESP flow cytometer equipped with EXPO™ 32 MultiCOMP software, version 1.2 (Beckman Coulter, Brea, CA, USA). Th17 cells were defined as CD3 + CD4 + IL-17A + cells. Cell labelling levels were defined as: low, < 30% of Th17 cells positive for marker; relatively high, 30 -60% positive; and high, > 60% positive.
The frequency of Th17 cells in the PBMCs from patients with multiple myeloma who achieved complete or partial remission after chemotherapy was examined by flow cytometry.
ENZYME-LINKED IMMUNOSORBENT ASSAY
Plasma concentrations of IL-1β, IL-6, IL-17 and IL-23 were measured by enzyme-linked immunosorbent assay (eBioscience) according to the manufacturer's instructions. All samples were measured in triplicate.
STATISTICAL ANALYSES
Data were presented as mean ± SD. All analyses were performed using SPSS ® software version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Student's t-test was used to test for differences between groups, with a P-value < 0.05 considered statistically significant.
Results
The study recruited 30 patients with newly ). The frequency of Th17 cells in gated CD3 + CD4 + cells was significantly higher in patients than in healthy control subjects (4.51 ± 1.71% versus 1.55 ± 0.63%; P < 0.01; Fig. 1 ). The frequency of Th17 cells in the 16 patients who achieved complete or partial remission was significantly reduced after chemotherapy (P < 0.01; Fig. 2) .
The relationships between the frequency of Th17 cells and various clinicopathological characteristics across the study population are shown in Table 1 . There was no relationship between the proportion of Th17 cells and patient age or gender. Th17 cell numbers were significantly associated with serum LDH concentration, serum creatinine concentration and tumour stage (P < 0.05 for each comparison).
The percentages of Th17 cells that were positive for cell surface markers and cytokines are shown in Table 2 . Due to the high cost of testing, phenotype analysis was performed in only one control subject; in addition, blood samples for phenotype analysis were only available from four patients with multiple myeloma. The phenotype of circulating Th17 cells in patients with multiple myeloma was similar to that observed in the healthy control subject, with the exception of CD25, HLA-DR, FoxP3 and PD-1, for which concentrations were lower in the control subject. Plasma concentrations of the Th17associated cytokines IL-1β, IL-6, IL-17 and IL-23 are shown in Table 3 . Cytokine concentrations were significantly higher in patients with multiple myeloma than in healthy control subjects (P < 0.01 for all comparisons).
Discussion
Multiple myeloma is a common tumour, accounting for about 1% of all human Data presented as mean ± SD. TGF, transforming growth factor; CXCR4, chemokine C-X-C motif receptor 4; CCR, chemokine C-C motif receptor; HLA, human leucocyte antigen; FoxP3, forkhead box P3; PD-1, programmed cell death-1; B7-H1, B7 homologue 1; B7-H4, B7 homologue 4. 
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malignant diseases and 10 -15% of haematological malignancies. 13 The introduction of new drugs, such as the proteasome inhibitor bortezomib, has improved the clinical response rate. 14 Multiple myeloma remains incurable, with frequent relapses, emphasizing the urgent need for more effective therapies. Immunotherapy is potentially more effective and targeted than traditional chemotherapy, and has become the focus of recent research. Little progress has been made, however, due to the presence of immunosuppressive mechanisms. 15 Further studies are needed to investigate interactions between the host immune system and the developing tumour, in cancer patients.
The Th17 cells have emerged as an important arm of the adaptive immune response involved in many pathological processes, including inflammatory and autoimmune diseases, 7,8 but relatively little is known about their specific roles in human tumour immunity. Kryczek et al. 16 reported that tumour-associated Th17 levels correlate positively with microenvironmental Th1 cells, cytotoxic CD8 + T cells and naturalkiller T cells, and negatively with regulator T cells. In addition, Th17 cells were the sole source of IL-17 in ascites in patients with ovarian cancer, and the level of IL-17 in ascites correlated positively with patient survival. 16 A high level of Th17-mediated inflammation has been associated with a lower pathological Gleason score, 17 and the accumulation of Th17 cells in malignant pleural effusion predicted improved survival in patients with lung adenocarcinoma or squamous cell carcinoma. 18 These studies suggest that Th17 cells are protective in tumour immunity. In contrast, a study of patients with hormone-resistant prostate cancer demonstrated a highly significant correlation between a higher prevaccination frequency of IL-17-producing T cells and a shorter time to metastatic progression, after receiving active whole-cell immunotherapy. 19 Dendritic cells have been shown to induce the expansion of polyfunctional IL-17producing T cells in multiple myeloma. 20 In addition, IL-17 promoted myeloma cell growth and colony formation via the IL-17 receptor, and increased in vivo growth, in a murine xenograft model of human multiple myeloma. 21 The Th17 cell phenotype was found to be a key predictor of lytic bone disease in multiple myeloma. 22 The frequency of Th17 cells was increased in the PBMCs of patients with multiple myeloma compared with healthy controls in the present study, and these data are consistent with those obtained in another study. 21 In addition, the plasma concentrations of a number of Th17-associated cytokines (IL-1β, IL-6, IL-17 and IL-23) were significantly elevated in patients compared with healthy control subjects in the current study. IL-6 is an essential growth and survival factor for myeloma, and serum IL-6 concentration is an independent factor associated with poor prognosis in multiple myeloma. 23 IL-17 -the hallmark of Th17 cells -has been shown to promote tumour growth, 24 and high intratumoural IL-17 levels are correlated with higher blood-vessel density and shorter survival in patients with nonsmall cell lung cancer. 25 The increased concentration of Th17-related cytokines coincided with the increased prevalence of Th17 cells in the current study, and may have contributed to the pathogenesis of multiple myeloma.
The Th17 cells had low levels of TGF-β labelling in the current study, but high (or relatively high) levels of polyfunctional effector cytokine labelling, including IL-2, IL-4, IL-10 and IFN-γ. The high levels of CD45RO, together with low levels of CD45RA, indicated that the cells were memory T cell-like. 26 
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positive for the homing molecules CXCR4, CCR6 and CCR7, and positive for CD62L but not CCR5; these homing molecules may be associated with Th17 cell migration. 16 The finding that Th17 cells had high or relatively high labelling with CD95, CD95L, CD25, HLA-DR and granzyme B suggests that these cells have several characteristics of 'conventional' effector T cells. 27 The high levels of FoxP3, PD-1 and B7-H4 labelling suggest that Th17 cells may bring about immune suppression through multiple pathways. Data from the present study are partially inconsistent with data obtained from patients with ovarian cancer, 16 but this discrepancy might be explained by the different tumour types in these studies.
The current study found that the increased Th17 cell frequencies in untreated patients were reduced when these patients achieved complete or partial remission after chemotherapy, which suggested that measurement of Th17 cell frequency may be useful in evaluating therapeutic effect. These results also suggested that the number of Th17 cells might be related to tumour burden, in line with the findings of other investigators. 28 The proportion of Th17 cells was correlated with serum LDH concentration, serum creatinine concentration and tumour stage in the current study. These parameters have been shown to reflect tumour-bearing status, and to predict prognosis and therapeutic outcome, 29 suggesting that Th17 cells may be associated with disease progression in multiple myeloma.
In conclusion, this study demonstrated significantly increased numbers of Th17 cells in patients with multiple myeloma, together with increased levels of Th17-associated cytokines. There was a significant relationship between the proportion of circulating Th17 cells and tumour stage, serum LDH concentration and serum creatinine concentration. Th17 cells may represent an important immunotherapeutic target in multiple myeloma. Additional studies -involving greater numbers of patients with multiple myeloma and control subjects -are required to prove the results presented here.
